CytomX Therapeutics, Inc. (CTMX)

Over the past six months, CytomX Therapeutics' stock has increased by 170.00%. The stock price increased by 573.81% from February 7, 2025, to February 6, 2026. Key events include a $100 million stock offering in May 2025, a Q3 2025 earnings report with revenue of $6 million and an EPS loss of $0.09, pipeline updates for CX-2051, and an analyst price target increase to $8.67 per share as of February 4, 2026.

As a clinical-stage biopharmaceutical company, CytomX Therapeutics' revenue is primarily driven by research and development progress, collaboration agreements, and licensing agreements. Traditional demand seasonality is not directly applicable, as financial inflows are linked to pipeline advancement and strategic choices of partners.

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, operating within the Health Technology sector. The company develops masked, conditionally activated biologics designed to localize to the tumor microenvironment. Its Probody platform enhances the safety and efficacy of antibody-based therapies by activating only within tumors. The company's clinical-stage pipeline includes CX-2051, CX-904, CX-801, Pacmilimab (CX-072), and CX-2009.

CytomX Therapeutics, Inc. is headquartered in South San Francisco, California, United States. The company has collaborations to support global clinical development and manufacturing, with trials conducted across North America and Europe.

CytomX Therapeutics has a generally positive brand reputation, with a consensus rating of "Moderate Buy" based on 7 buy ratings and 1 hold rating. The company scored higher than 78% of companies evaluated by MarketBeat. While there are mentions of "volatile collaboration revenue" and "recent safety concerns" in the biotech sector, no specific events explicitly damaging CytomX's reputation were detailed. The company emphasizes its commitment to diversity, equity, and inclusion.

Institutional investors hold approximately 80.25% of CytomX Therapeutics, Inc. stock. Major institutional owners include VR Adviser, LLC, Fmr Llc (Fidelity), Tang Capital Management Llc, Perceptive Advisors Llc, Vanguard Group Inc, Orbimed Advisors Llc, Commodore Capital Lp, and Longitude Capital Management Co., LLC.